Resultados de procura - David Lucas
- Mostrando 1 - 20 Resultados de 45
- Go to Next Page
-
1
-
2
Seafarers’ Occupational Noise Exposure and Cardiovascular Risk. Comments to Bolm-Audorff, U.; et al. Occupational Noise and Hypertension Risk: A Systematic Review and Meta-Analysis... por David, Lucas, Brice, Loddé, Richard, Pougnet, Jean Dominique, Dewitte, Dominique, Jégaden
Publicado 2021Text -
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction por John C. Byrd, Shinichi Kitada, Ian W. Flinn, Jennifer L. Aron, Michael Pearson, David Lucas, John C. Reed
Publicado 2002Artigo -
11
-
12
Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia por Tasneem Motiwala, Sarmila Majumder, Huban Kutay, David S. Smith, Donna Neuberg, David Lucas, John C. Byrd, Michael R. Grever, Samson T. Jacob
Publicado 2007Artigo -
13
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia por Amy J. Johnson, David Lucas, Natarajan Muthusamy, Lisa L. Smith, Ryan B. Edwards, Michael De Lay, Carlo M. Croce, Michael R. Grever, John C. Byrd
Publicado 2006Artigo -
14
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism... por Kristie A. Blum, Sin‐Ho Jung, Jeffrey L. Johnson, Thomas S. Lin, Eric D. Hsi, David Lucas, John C. Byrd, Bruce D. Cheson, Nancy L. Bartlett
Publicado 2010Artigo -
15
Daunorubicin‐Loaded DNA Origami Nanostructures Circumvent Drug‐Resistance Mechanisms in a Leukemia Model por Patrick D. Halley, Christopher R. Lucas, Emily M. McWilliams, Matthew J. Webber, Randy A. Patton, Cömert Kural, David Lucas, John C. Byrd, Carlos E. Castro
Publicado 2015Artigo -
16
Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Ad... por John C. Byrd, John G. Gribben, Bercedis L. Peterson, Michael R. Grever, Gerard Lozanski, David Lucas, Ben Lampson, Richard A. Larson, Michael A. Caligiuri, Nyla A. Heerema
Publicado 2005Artigo -
17
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL por Shih-Shih Chen, Rainer Claus, David Lucas, Lianbo Yu, Qian Jiang, Amy S. Ruppert, Derek A. West, Katie Williams, Amy J. Johnson, Fred Sablitzky, Christoph Plass, John C. Byrd
Publicado 2010Artigo -
18
Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease por Javier Bolaños‐Meade, David A. Jacobsohn, Jeffrey Margolis, Adam Ogden, M. Guillaume Wientjes, John C. Byrd, David Lucas, Viki Anders, Michele Phelps, Michael R. Grever, Georgia B. Vogelsang
Publicado 2005Artigo -
19
As dificuldades na abordagem integral à saúde LGBTQIA+ por David Lucas Viana Garcia, Sofia Maria Brito Cal Muinhos, Palloma Linhares de Almeida, Ravenna Gomes Oliveira de Alencar, E Silva, Yasmim Farias de Miranda, Layza de Souza Chaves Deininger
Publicado 2024Artigo -
20
Persistence of<i>DNMT3A</i>R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia por Bhavana Bhatnagar, Ann‐Kathrin Eisfeld, Deedra Nicolet, Krzysztof Mrózek, James S. Blachly, Shelley Orwick, David Lucas, Jessica Kohlschmidt, William Blum, Jonathan E. Kolitz, Richard M. Stone, Clara D. Bloomfield, John C. Byrd
Publicado 2016Artigo
Ferramentas de procura:
Materias Relacionadas
Biology
Leukemia
Medicine
Chronic lymphocytic leukemia
Internal medicine
Cancer research
Immunology
Biochemistry
Gene
Genetics
Chemotherapy
Oncology
Pharmacology
Gastroenterology
In vivo
Lymphoma
Biotechnology
Chemistry
Cyclophosphamide
DNA methylation
Gene expression
In vitro
Apoptosis
Fludarabine
Computational biology
Methylation
Rituximab
Toxicity
Astrobiology
Cancer